News

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic ...
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion.
Pluvicto, a drug Novartis gained by acquiring the biotechnology company Endocyte six years ago, is one of the pharma giant’s priority products. Known as a radiopharmaceutical, it links a ...
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...
Pluvicto works by attaching to the PSMA protein found on the surface of the prostate cancer cells. He said: “I asked the radiation oncologist a couple of weeks ago about the drug I’m on, which ...
Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC 1. Novartis is ...
Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177) 5,7. After administration into the ...
This is welcome news for the more than 12,000 United States military veterans who are diagnosed with prostate cancer annually. The Veteran’s Health Administration (VA) provides access to Pluvicto for ...
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...